Shots:

• The first patient has enrolled in P-III TETON study to evaluate the safety and efficacy of treprostinil (Inhalation Solution) or PBO in a ratio (1:1) in 396 adult patients with IPF
• The 1EPs of the study is the change in FVC from baseline@ 52 wks. and 2EPs include time to clinical worsening- time to first acute exacerbation- OS @ 52wks.- change in percent predicted FVC from baseline & change in KBILD
• The study is designed to validate the antifibrotic effects of treprostinil in IPF patients while FDA has approved Tyvaso for both pulmonary AH & PH-ILD and has granted OD designation for IPF

  | Ref: PR Newswire | Image: United Therapeutics